Education
About Us
Working with TipRanks
Follow Us
Nautilus Biotechnolgy (NAUT)
NASDAQ:NAUT
NAUT Stock Chart & Stats
$1.98
$0.08(4.65%)
At close: 4:00 PM EST
$1.98
$0.08(4.65%)
Day’s Range― - ―
52-Week Range$0.62 - $2.54
Previous CloseN/A
Volume36.21K
Average Volume (3M)394.63K
Market Cap
$200.83M
Enterprise Value-$28.20M
Total Cash (Recent Filing)$131.43M
Total Debt (Recent Filing)$27.00M
Price to Earnings (P/E)―
Beta2.01
Next Earnings
Feb 19, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding126,305,120
10 Day Avg. Volume378,207
30 Day Avg. Volume394,629
Financial Highlights & Ratios
PEG Ratio-0.30
Price to Book (P/B)1.01
Price to Sales (P/S)0.00
P/FCF Ratio-3.44
Enterprise Value/Market Cap-0.14
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.51
Enterprise Value/Ebitda0.55
Forecast
1Y Price Target
$2.50Price Target Upside26.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe cash runway is expected to support NAUT's ongoing R&D activities and extend into '27.
Partnerships And CollaborationsNew collaborations were another area of focus, and the company noted a collaborator at the Buck Institute for Research on Aging will be presenting results using NAUT's platform at the HUPO World Congress.
Product Development SuccessManagement highlighted the recent proteoform product success with tau, increasing customer interest, and confidence in ongoing product development for the more important proteome platform.
Bears Say
Nautilus Biotechnolgy News
NAUT FAQ
What was Nautilus Biotechnolgy’s price range in the past 12 months?
Nautilus Biotechnolgy lowest stock price was $0.62 and its highest was $2.54 in the past 12 months.
What is Nautilus Biotechnolgy’s market cap?
Nautilus Biotechnolgy’s market cap is $200.83M.
When is Nautilus Biotechnolgy’s upcoming earnings report date?
Nautilus Biotechnolgy’s upcoming earnings report date is Feb 19, 2026 which is in 77 days.
How were Nautilus Biotechnolgy’s earnings last quarter?
Nautilus Biotechnolgy released its earnings results on Oct 28, 2025. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.15 by $0.04.
Is Nautilus Biotechnolgy overvalued?
According to Wall Street analysts Nautilus Biotechnolgy’s price is currently Undervalued.
Does Nautilus Biotechnolgy pay dividends?
Nautilus Biotechnolgy does not currently pay dividends.
What is Nautilus Biotechnolgy’s EPS estimate?
Nautilus Biotechnolgy’s EPS estimate is -0.14.
How many shares outstanding does Nautilus Biotechnolgy have?
Nautilus Biotechnolgy has 126,305,120 shares outstanding.
What happened to Nautilus Biotechnolgy’s price movement after its last earnings report?
Nautilus Biotechnolgy reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.15. Following the earnings report the stock price went up 5.926%.
Which hedge fund is a major shareholder of Nautilus Biotechnolgy?
Currently, no hedge funds are holding shares in NAUT
Nautilus Biotechnolgy Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.50 (26.26% Upside)
$2.50 (26.26% Upside)
Insider Transactions
Bought Shares
Worth $153.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 10.7%
Last 30 Days ▲ 10.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.20%
12-Months-Change
Fundamentals
Return on Equity
-32.00%
Trailing 12-Months
Asset Growth
-21.84%
Trailing 12-Months
Company Description
Nautilus Biotechnolgy
Nautilus Biotechnology (NAUT) is a pioneering company in the biotechnology sector, focused on revolutionizing the field of proteomics. The company's core product is its proprietary platform designed to comprehensively analyze and quantify proteins with unprecedented sensitivity and scale. This breakthrough technology aims to accelerate biomedical research and development, enabling deeper insights into the proteome that can drive advancements in drug discovery, diagnostics, and personalized medicine.
NAUT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized significant scientific and operational progress, expansion of strategic partnerships, and positive market feedback, tempered by the acknowledgment of limited near-term revenue expectations.View all NAUT earnings summariesNAUT Stock 12 Month Forecast
Average Price Target
$2.50
▲(26.26% Upside)
Technical Analysis
VistaGen Therapeutics
―
Adverum Biotechnologies
―
Kalaris Therapeutics
―
Seer
―
Acumen Pharmaceuticals
―
Ownership Overview
35.50% Insiders
2.83% Mutual Funds
39.47% Other Institutional Investors
20.42% Public Companies and
Individual Investors